Show simple item record

dc.contributor.authorShankaran, V
dc.contributor.authorXiao, H
dc.contributor.authorBertwistle, D
dc.contributor.authorZhang, Y
dc.contributor.authorYou, M
dc.contributor.authorAbraham, P
dc.contributor.authorChau, I
dc.coverage.spatialUnited States
dc.date.accessioned2022-09-13T08:59:48Z
dc.date.available2022-09-13T08:59:48Z
dc.date.issued2020-11-26
dc.identifier10.1007/s12325-020-01567-9
dc.identifier.citationAdvances in Therapy, 2020, 38 (1), pp. 707 - 720en_US
dc.identifier.issn0741-238X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5444
dc.identifier.eissn1865-8652
dc.identifier.eissn1865-8652
dc.identifier.doi10.1007/s12325-020-01567-9
dc.identifier.doi10.1007/s12325-020-01567-9
dc.description.abstractINTRODUCTION: Management of locally advanced, unresectable, or metastatic (adv/met) esophageal adenocarcinoma (EAC) follows clinical guidance for gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, evidence for these guidelines is based largely on patients with adv/met GC/GEJC, and generally excludes patients with EAC. It is currently unclear whether patients with adv/met GC/GEJC and adv/met EAC have similar demographics and clinical outcomes in real-world practice. METHODS: Adult patients diagnosed with adv/met GC/GEJC and adv/met EAC between January 1, 2011 and November 30, 2018 were identified (Flatiron Health database); patients with confirmed human epidermal growth factor receptor 2 (HER2)-positive tumors were excluded, and index was date of adv/met diagnosis. Median overall survival (OS) from start of first-line therapy until death/censoring was estimated by the Kaplan-Meier method. Multivariable analysis (Cox proportional hazards) was conducted to identify factors associated with OS. RESULTS: In total, 3052 patients were identified (adv/met GC/GEJC, n = 2083; adv/met EAC, n = 969). Patients with EAC were more likely to be male, have a history of smoking, have a higher body weight and body mass index, and were less likely to be Hispanic/Latino or Medicaid enrollees than patients with GC/GEJC. A similar proportion of patients with adv/met GC/GEJC (75%; n = 2326) and adv/met EAC (77%; n = 1573) received first-line therapy. Fluoropyrimidine plus platinum combinations were the most frequent first-line regimen in both groups (36%). Median OS was similar for patients with adv/met GC/GEJC and adv/met EAC (9.7 vs. 9.1 months, respectively; hazard ratio [95% confidence interval] 0.96 [0.87-1.06]; p = 0.4320). CONCLUSION: Despite minor differences in baseline demographics, clinical outcomes for patients with adv/met GC/GEJC and EAC are similar. This supports the inclusion of patients with adv/met EAC in clinical trials assessing adv/med GC/GEJC.
dc.formatPrint-Electronic
dc.format.extent707 - 720
dc.languageeng
dc.language.isoengen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofAdvances in Therapy
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectEsophageal adenocarcinoma
dc.subjectGastric cancer
dc.subjectGastroesophageal junction cancer
dc.subjectAdenocarcinoma
dc.subjectAdult
dc.subjectEsophageal Neoplasms
dc.subjectEsophagogastric Junction
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectStomach Neoplasms
dc.titleA Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-11-10
dc.date.updated2022-09-13T08:58:31Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1007/s12325-020-01567-9en_US
rioxxterms.licenseref.startdate2020-11-26
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/33244736
pubs.issue1
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1007/s12325-020-01567-9
pubs.volume38
dc.contributor.icrauthorChau, Ian
icr.provenanceDeposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectabl.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/